Please ensure Javascript is enabled for purposes of website accessibility

Why Mesoblast Limited Stock Is Jumping Today

By Prosper Junior Bakiny - Apr 30, 2021 at 4:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced positive results from a clinical trial.

What happened?

Shares of Mesoblast Limited (MESO 10.77%) are rising sharply on Friday after the company reported positive results from a clinical trial for one of its pipeline candidates, remestemcel-L. The biotech's stock was up 7.3% as of 3:22 p.m. EDT, after soaring by as much as 24.5% earlier in today's trading session.

So what

In a clinical trial investigating the efficacy of remestemcel-L in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS), the medicine was shown to reduce mortality by 46% in patients under the age of 65 through day 60, but not in those aged 65 and older. When combined with dexamethasone, remestemcel-L reduced mortality by 75% and increased ventilation-free days in patients under the age of 65 through day 60, compared to those treated with dexamethasone alone.

Illustration of a microscopic view of coronavirus particles

Image source: Getty Images.

Mesoblast CEO Silviu Itescu said, "Reduction in mortality in mechanically ventilated patients under 65 years old remains a critical unmet need since as many as 72% of currently hospitalized patients across the US with COVID-19 are in this age category." With these results in its back pocket, the biotech company plans to discuss a potential path toward regulatory approval or emergency use authorization (EUA) for remestemcel-L with the U.S. Food and Drug Administration.

Now what

Remestemcel-L could provide an immediate boost to Mesoblast's financial results if it earns EUA. The company does have other promising pipeline candidates, too. Earlier this year, it announced positive results from a phase 3 clinical trial for rexlemestrocel-L in treating patients with chronic low back pain due to degenerative disc disease. Thanks to these results, Mesoblast boasts several short-term catalysts that could send its stock price even higher, which means it might be worth it to keep an eye on this company in the coming months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mesoblast Limited Stock Quote
Mesoblast Limited
$2.88 (10.77%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.